Ascendis Pharma A/S
ASND
$207.98
$7.483.73%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 39.24% | 68.84% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 39.24% | 68.84% | |||
| Cost of Revenue | -26.77% | 93.61% | |||
| Gross Profit | 55.64% | 63.64% | |||
| SG&A Expenses | 8.61% | 14.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.07% | 10.91% | |||
| Operating Income | 121.39% | 45.20% | |||
| Income Before Tax | -68.82% | 59.65% | |||
| Income Tax Expenses | -3.17% | 291.15% | |||
| Earnings from Continuing Operations | -61.69% | 55.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -61.69% | 55.72% | |||
| EBIT | 121.39% | 45.20% | |||
| EBITDA | 131.80% | 47.36% | |||
| EPS Basic | -60.90% | 56.04% | |||
| Normalized Basic EPS | -68.01% | 59.94% | |||
| EPS Diluted | -60.90% | 56.04% | |||
| Normalized Diluted EPS | -77.61% | 62.11% | |||
| Average Basic Shares Outstanding | 0.50% | 0.73% | |||
| Average Diluted Shares Outstanding | -4.94% | 6.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||